Okmetic Oyj: INTERIM REPORT 1 JANUARY - 31 MARCH 2013: SOLID BEGINNING OF THE YEAR DESPITE STRUCTURAL CHANGES OF BUSINESS OPERATIONS

OKMETIC OYJ STOCK EXCHANGE RELEASE    25 APRIL 2013 AT 8.00 A.M.

INTERIM REPORT 1 JANUARY - 31 MARCH 2013: SOLID BEGINNING OF THE YEAR DESPITE STRUCTURAL CHANGES OF BUSINESS OPERATIONS

Unless otherwise stated, figures in parenthesis refer to the corresponding period of the previous year.

JANUARY-MARCH IN BRIEF:

• Net sales amounted to 16.4 (18.9) million euro, down 13.2%.
• Silicon wafer shipments amounted to 15.5 (15.2) million euro, up 1.7%.
• Operating profit was 1.4 (1.5) million euro corresponding to 8.4% of net sales.
• Profit for the period was 1.2 (0.7) million euro.
• Basic earnings per share was 0.07 (0.04) euro.
• Net cash flow from operations amounted to 0.8 (-1.0) million euro.

PROJECTIONS FOR THE NEAR FUTURE

In 2013, the semiconductor industry's demand is estimated to take an upward turn again, and the sensor industry is forecast to continue on its growth track.

The demand for sensor wafers manufactured by Okmetic is estimated to be fairly stable throughout 2013. Due to normal seasonal fluctuation, the demand for semiconductor wafers will be slower in the beginning of the year and is likely to pick up in the second quarter.

Okmetic strives to outgrow the markets in its core business as a manufacturer of demanding silicon wafers in the current financial year as well. Technology sales, instead, have contracted significantly as a result of the solar cell industry's plummeted price level, which means structural change in the company's business. In 2013, the company's business will largely consist of silicon wafer sales. Nevertheless, the forecast growth of silicon wafer sales will not fully compensate for the steep decline in technology sales, which is why the company's net sales will decrease in 2013. Technology sales are reported under the title Other business as of 1 January 2013 due to their diminished weigh and varying content.     

The company retains existing guidance, according to which net sales and operating profit for 2013 are estimated to remain under the level of 2012.
                   
PRESIDENT KAI SEIKKU:

"In the first quarter, net sales decreased as anticipated due to considerable decline in technology sales. Demand for silicon wafers was low in the beginning of the year but, nevertheless, showed minor growth in relation to the comparison period. It was positive that the operating profit developed slightly better than the company expected. In addition, profit for the period, earnings per share, and net cash flow from operations strengthened clearly compared to the corresponding period last year. Net cash flow was improved by the reimbursement of income tax advances from 2012.

Reasonably good profitability was primarily based on successful cost management. Minor extraordinary items and exchange rate changes improved the result of the first quarter. By contrast, manufacturing of epitaxial wafers continued to be unprofitable at the Allen production plant.

Sensor wafer sales showed strong, over 10 percent growth in the beginning of the year. Due to good sales growth and decline in technology sales, the sensor wafers' share of net sales exceeded the level of 50 percent for the first time and amounted to as much as 60 percent. This development complies with Okmetic's long-term strategy. Despite the global macroeconomic challenges, demand outlook in the sensor industry is positive, since the amount of sensor applications continues to increase in many areas of life. Okmetic is a market leader and a forerunner as a supplier of demanding sensor wafers.

Demand for semiconductor wafers was low in the beginning of the year, as is seasonally typical. Asia's relative proportion of the company's entire net sales declined in the period under review. This was particularly due to the discontinuation of technology sales, or solar crystal shipments, that have been previously targeted to Asia, but also due to low demand in the Japanese market. The first quarter of the calendar year is typically the last in Japan, which is when the market usually slows down.

The silicon wafer market will partly pick up in the second quarter, and at the moment it seems that demand will be strongest in the third quarter. The lower-than-anticipated demand in the PC market and for certain consumer electronics devices create uncertainty of demand in the ongoing second quarter.

The company is currently in discussions to licence crystal growing expertise. Possible transactions will be communicated separately."

KEY FIGURES

1,000 euro	1 Jan- 31 Mar, 2013	1 Jan- 31 Mar, 2012	1 Jan- 31 Dec, 2012	1 Jan- 31 Dec, 2011
Net sales	16,403	18,902	83,074	83,186
Operating profit before depreciation (EBITDA)	2,725	3,052	13,864	18,069
Operating profit	1,373	1,535	8,018	11,817
  % of net sales	8.4	8.1	9.7	14.2
Profit for the period	1,218	712	5,089	10,235
Basic earnings per share, euro	0.07	0.04	0.31	0.61
Net cash flow from operating activities	811	-996	9,425	11,691
Net interest- bearing liabilities	2,003	-6,071	-1,688	-10,257
Equity ratio, %	67.3	79.2	72.2	78.9
Average number of personnel during the period	358	351	368	363

MARKETS

Customer industries sensor and semiconductor industries

Sensor industry

According to different estimates, the sale value of sensor industry increased by approximately 6-10 percent in 2012 compared to the previous year. The development of sensor sales has been positively influenced by the increased use of micro sensors in many consumer electronics products. In 2013, the sale value of sensor industry is estimated to increase by 8-11 percent compared to 2012. In terms of volume, the sensor shipments are likely to clearly rise to a record level in 2013. For the next few years, the sale value of sensor industry is estimated to grow 8-13 percent annually. (IHS, Yole)

Semiconductor industry

In the last quarter of 2012, the semiconductor industry's sales in US dollars followed the seasonal fluctuation pattern typical of the industry. Even though the sales in the last quarter of 2012 grew from the previous year, the sales for the whole year were 2.7 percent below the level of the previous year (SIA). The markets are expected to recover from the second quarter of 2013 onwards and therefore, the growth estimates for the whole year settle between 4.0 and 5.6 percent (TSMC, WSTS, Gartner, iSuppli). The growth is expected to continue also in the following year. 

Silicon wafer market

According to the report of SMG, the group of silicon wafer suppliers in SEMI (a global umbrella organisation for semiconductor materials and equipment industry), the surface area of silicon wafer shipments in 2012 calculated in square inches equaled the previous year's surface area as was estimated earlier. As a consequence of price erosion the silicon wafer market measured in US dollars decreased in 2012. The surface area is estimated to grow around 4.4 percent in 2013 (Gartner).

Okmetic's central customer areas in the silicon wafer market

In line with its strategy, Okmetic seeks for special areas of the entire silicon wafer market that have greater growth rates than the market average and in which the company has special expertise. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS industry is Okmetic's central growth area. The MEMS market grows as portable consumer products, automotive electronics, and industrial process control increase.

In the semiconductor market, Okmetic's growth areas include discrete and power semiconductors. The growth areas of these markets are i.a. components used in the production of renewable energy, increasing automotive electronics, portable consumer products, as well as different solutions related to power supply and efficiency improvement.

CHANGE IN SALES REPORTING PER CUSTOMER AREA

Okmetic has changed its sales reporting per customer area as of the beginning of 2013. According to the new policy, technology sales are reported under the title Other business because of their diminished weigh and varying content.

SALES

In January-March, Okmetic's net sales were 16.4 (18.9) million euro. The net sales decreased by 13.2 percent (decrease of 14.3%) compared to the corresponding period last year mainly as a result of declining other business. Okmetic's market share remained stable in product areas important to the company, and the sales started to pick up towards the end of the first quarter as was anticipated.

Sales per customer area

	1 Jan- 31 Mar,  2013	1 Jan- 31 Mar,  2012	1 Jan- 31 Dec,  2012	1 Jan- 31 Dec,  2011
Sensors	60%	46%	47%	46%
Semiconductors	37%	34%	38%	35%
Other business	3%	20%	15%	19%

The demand for sensor wafers continued strong and in January-March, the value of shipments was 10.5 percent higher than in the corresponding period last year. The demand for sensor wafers is estimated to continue solid throughout the year 2013.

The downturn of the semiconductor industry began to gradually change direction in the end of the first quarter, which improved semiconductor wafer sales. Because of low demand during January-February, the value of shipments in January-March was 10.1 percent lower than in the corresponding period last year.

During January-March, the value of shipments in other business was 0.5 million euro.

Sales per market area

	1 Jan- 31 Mar,  2013	1 Jan- 31 Mar,  2012	1 Jan- 31 Dec, 2012	1 Jan- 31 Dec, 2011
North America	39%	36%	37%	37%
Europe	  36%	26%	27%	30%
Asia	 25%	38%	35%	33%

In the first quarter, Okmetic's sales were strongest in North America and Europe. Asia's relative proportion of net sales decreased in the period under review.

PROFITABILITY

January-March

In January-March, Okmetic's operating profit was 1.4 (1.5) million euro. The operating profit accounted for 8.4 (8.1) percent of net sales. Profit for the period was 1.2 (0.7) million euro. Basic earnings per share was 0.07 (0.04) euro. Diluted earnings per share was 0.07 (0.04) euro.

FINANCING

The company's financial position is good. In January-March, net cash flow from operations amounted to 0.8 (-1.0) million euro. Changes in working capital weakened the net cash flow by 2.6 (3.9) million euro. The reimbursement of income tax advances from 2012 improved the net cash flow of the period by 1.1 million euro.

On 31 March 2013, the company's interest-bearing liabilities amounted to 15.9 (1.0) million euro.

Okmetic announced in January that it has signed a five-year loan agreement for 10 million euro. The loan is used for the earlier announced investments and general corporate purposes.

At the end of the period, the cash and cash equivalents amounted to 13.9 (7.2) million euro. On 31 March 2013, the company's cash and cash equivalents were 2.0 million euro lower than the interest-bearing liabilities (on 31 March 2012, the cash and cash equivalents were 6.2 million euro higher than the interest-bearing liabilities). The company has ensured the sufficiency of cash funds by a credit facility of 6.0 million euro. On 31 March 2013, 3.0 million euro of the credit facility was in use (on 31 March 2012 the credit facility was undrawn).

Return on equity amounted to 7.8 (4.6) percent. The company's equity ratio was 67.3 (79.2) percent. Equity per share was 3.80 (3.69) euro.

INVESTMENTS

In January-March, Okmetic's capital expenditure amounted to 2.6 (2.6) million euro. The investments concerned debottlenecking and automatisation of wafer production lines.

PRODUCT DEVELOPMENT

In January-March, the company expensed 0.6 (0.5) million euro in product development projects. Product development costs accounted for 3.9 (2.8) percent of the net sales. The product development costs have not been capitalised. The product development has been allocated to SOI wafers as well as high and low resistivity wafers.

PERSONNEL

In January-March, Okmetic employed 358 (351) people on average. At the end of the period, Okmetic employed 354 (352) people of which 313 worked in Finland, 36 in the US, four in Japan, and one in Hong Kong.

BUSINESS RISKS

There have been no essential changes in the company's near future business risks and uncertainties.

Okmetic's silicon wafer sales are targeted at the sensor and semiconductor producers in the electronics industry. The demand for semiconductor wafers is sensitive to economic fluctuations and changes in the market situation can be sudden and dramatic. The demand for sensor wafers is more stable. The proliferation of sensors in consumer electronics applications may, however, increase the susceptibility of this market too to economic fluctuations. Technology sales have in recent years been mainly crystal sales to the solar cell industry. Okmetic has existing polysilicon purchasing obligations partly until 2015. As the price level of the solar cell market has dropped, the validity of long-term polysilicon contracts typical of the industry may cause a price risk.

Okmetic's share of the global silicon wafer market is around one percent and the market prices have a notable effect on the price development of Okmetic's products. The company only has considerable pricing power with its own special products. The pricing of other wafers is mainly based on global market price.

Okmetic operates globally, and therefore the company's business operations are affected by risks due to exchange rate fluctuations, consisting of the cash flows of purchases and sales. A significant part of sales are conducted in US dollars. Despite hedging, the company remains exposed to exchange rate fluctuations.

Substantial volumes of electricity are used in Okmetic's production. Despite hedging, the company is exposed to fluctuations in the price of electricity.

SHARES AND SHAREHOLDERS

On 31 March 2013, Okmetic Oyj's paid-up share capital, as entered in the Finnish Trade Register, was 11,821,250.00 euro. The number of shares was 17,287,500. The shares have no nominal value attached. Each share entitles its holder to one vote at general meetings. The company has one class of shares. The company's shares are included in the Finnish book-entry securities system.

Major shareholders on 31 March 2013	Â	Â
Â	Shares, pcs	Share, %
Ilmarinen Mutual Pension Insurance Company	1,549,985	9.0
Oy Ingman Finance Ab	870,000	5.0
Mandatum Life Insurance Company Limited	800,000	4.6
The State Pension Fund	600,000	3.5
Nordea Nordic Small Cap Fund	517,660	3.0
Varma Mutual Pension Insurance Company	477,175	2.8
Etra-Invest Oy AbÂ	400,000	2.3
Okmetic Management Oy	400,000	2.3
Okmetic Oyj	227,946	1.3
Investment Fund Taaleritehdas Arvo Markka Osake	225,100	1.3
Foreign investors and nominee accounts held by custodian banks	2,919,789	16.9
Other	8,315,091	48.1
Total	17,287,500	100.0
Â	Â	Â

SHARE PRICE PERFORMANCE AND TRADING

A total of 1.0 (1.1) million shares were traded between 1 January and 31 March 2013, representing 5.8 (6.6) percent of the weighted average of share total of 17.3 (17.3) million during the period. The lowest quotation during the period was 4.33 (4.98) euro, and the highest 5.15 (6.01) euro, with the average being 4.71 (5.63) euro. The closing quotation for the period was 4.53 (5.82) euro. At the end of the period, the market capitalisation amounted to 78.3 (100.6) million euro.

DISCLOSURES OF HOLDINGS

On 12 March 2013 the total holdings that Oy Ingman Finance Ab (Trade Register number 2241895-0) had in the company rose to 5.03 percent.  

OWN SHARES AND DIRECTED SHARE ISSUES

On 12 February 2013, Okmetic Oyj's board of directors announced of its decision to transfer a total of 18,540 own shares held by the company as a part of the company's share-based incentive scheme for the executive management group, of which the company has given a stock exchange release on 8 February 2012. All the shares were issued to the members of the executive management group in deviation from the shareholders' pre-emptive rights (directed share issue).

The rewards of the share reward programme were paid in Okmetic shares and in a monetary amount covering taxes. The directed share issue without payment was executed in full as there was no consideration related to the issue.

At the end of the reporting period Okmetic held 209,406 (241,543) own shares, which is approximately (1.2) 1.4 percent of Okmetic's all shares and votes. 

More information relating to own shares and directed share issues can be found on the company website www.okmetic.com > Investors > Share information > Own shares.   

OTHER EVENTS IN THE INTERIM PERIOD

Okmetic's board of directors decided on the share reward programme for the executive management group for 2013 as a part of the company's incentive and commitment plan in its meeting on 11 February 2013. The purpose of the programme is to commit and incentivise the executive management group to grow the shareholder value in the long run.

The programme's earning period is calendar year 2013. The possible rewards of the share reward programme will be paid in Okmetic shares and in a monetary amount covering the taxes in accordance with reaching the targets that have been set. The amount of the earned reward will be determined based on the realisation of the set targets and the possible reward will be paid to the persons in the programme after the financial statements for 2013 have been published. The amount of the rewards corresponds to a maximum of 150,000 shares.

EVENTS AFTER THE END OF THE INTERIM PERIOD

Annual general meeting on 10 April 2013

Okmetic Oyj's annual general meeting, which was held on 10 April 2013, adopted the annual accounts and the consolidated annual accounts for 2012 and discharged the company's management from liability. It was decided that a dividend of 0.25 euro per share would be distributed for 2012. The dividend was paid on Monday 22 April 2013. The annual general meeting decided also, in accordance with the proposal of the board of directors, to authorise the board of directors to decide upon its discretion on the payment of a dividend, should the company's financial situation permit this. The additional dividend, including all possible separate decisions on dividend payment, may amount up to a maximum of 0.40 euro per share and 15,000,000 euro in total. Moreover, the general meeting approved the proposal of the board of directors to authorise the board of directors to decide on the repurchase and/or the acceptance as pledge of the company's own shares as well as on the issuance of shares, the transfer of the company's own shares, and the issuance of special rights entitling to shares.

It was decided that there would be five members on the company's board of directors. Mr. Tapani Järvinen, Mr. Hannu Martola, Ms. Mervi Paulasto-Kröckel, Mr. Mikko Puolakka, and Mr. Henri Österlund were re-elected as members of the board of directors until the end of the next annual general meeting. The board of directors elected Henri Österlund as its chairman and Tapani Järvinen as its vice chairman in its organising meeting held immediately after the annual general meeting.

Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor, with APA Mikko Nieminen having the principal responsibility.

Authorisations given to the board of directors and other decisions of the annual general meeting have been disclosed in a stock exchange release published on 10 April 2013.

CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 MARCH 2013 (unaudited)

ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same accounting policies as in the financial statements for 2012 except for the effect of changes required by the adoption of certain new or revised standards and interpretations as of 1 January 2013, which have been described in financial statements 2012. The adoption of the new and revised standards and interpretations has not had an effect on the figures presented from the reporting period.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

1,000 euro	1 Jan- 31 Mar, 2013	1 Jan- 31 Mar, 2012	1 Jan- 31 Dec, 2012
Net sales	16,403	18,902	83,074
Cost of sales	-13,118	-14,851	-65,995
Gross profit	3,285	4,051	17,079
Other income and expenses	-1,911	-2,515	-9,061
Operating profit	1,373	1,535	8,018
Financial income and expenses	-97	-307	-418
Profit before tax	1,277	1,229	7,600
Income tax	-58	-517	-2,510
Profit for the period	1,218	712	5,089
Other comprehensive income:
Cash flow hedges	-47	127	128
Translation differences	316	-106	76
Other comprehensive income for the period, net of tax	269	21	204
Total comprehensive income for the period	1,487	733	5,293
Profit for the period attributable to:
Equity holders of the parent company	1,218	712	5,089
Total comprehensive income attributable to:
Equity holders of the parent company	1,487	733	5,293
Basic earnings per share, euro	0.07	0.04	0.31
Diluted earnings per share, euro	0.07	0.04	0.30

CONDENSED CONSOLIDATED BALANCE SHEET

1,000 euro	31 Mar, 2013	31 Mar, 2012	31 Dec, 2012
Assets
Non-current assets
Property, plant and equipment	44,819	35,847	43,433
Intangible assets	739	83	636
Other receivables	2,712	3,696	3,089
Total non-current assets	48,270	39,626	47,159
Current assets
Inventories	15,760	14,963	13,526
Receivables	16,371	16,933	17,796
Cash and cash equivalents	13,859	7,154	7,288
Total current assets	45,990	39,049	38,610
Total assets	94,260	78,675	85,769
Equity and liabilities
Equity
Equity attributable to equity holders of the parent company
Share capital	11,821	11,821	11,821
Other equity	51,605	49,914	50,038
Total equity	63,426	61,735	61,860
Liabilities
Non-current liabilities	12,950	3,272	5,314
Current liabilities	17,884	13,669	18,595
Total liabilities	30,834	16,940	23,909
Total equity and liabilities	94,260	78,675	85,769

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

1,000 euro	1 Jan- 31 Mar, 2013	1 Jan- 31 Mar, 2012	1 Jan- 31 Dec, 2012
Cash flows from operating activities:
Profit before tax	1,277	1,229	7,600
Adjustments	1,223	2,192	6,482
Change in working capital	-2,626	-3,878	-1,124
Financial items	-13	11	-47
Tax paid	950	-520	-3,486
Net cash from operating activities	811	-966	9,425
Cash flows from investing activities:
Purchases of property, plant and equipment	-4,131	-2,624	-10,983
Net cash used in investing activities	-4,131	-2,624	-10,983
Cash flows from financing activities:
Proceeds from long- term borrowings	9,990	-	-
Proceeds from short- term borrowings	23	-	3,043
Payments of finance lease liabilities	-109	-	-264
Other items	-	-	10
Dividends paid	-	-201	-4,862
Net cash used in financing activities	9,904	-201	-2,072
Increase (+) / decrease (-) in cash and cash equivalents	6,585	-3,791	-3,631
Exchange rate changes	-14	-313	-338
Cash and cash equivalents at the beginning of the period	7,288	11,257	11,257
Cash and cash equivalents at the end of the period	13,859	7,154	7,288

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Equity attributable to equity holders of parent company
1,000 euro	Share capital	Share pre- mium	Reserve for in- vested unre- stricted equity	Other re- serves  1)	Retained earnings	Total
Balance at 31 Dec, 2012	11,821	20,045	1,200	1,874	26,919	61,860
Profit for the period					1,218	1,218
Other com- prehensive income, net of tax:
Cash flow hedges				-47		-47
Translation differences				316		316
Total com- prehensive income for the period				269	1,218	1,487
Share-based payments					80	80
Balance at 31 Mar, 2013	11,821	20,045	1,200	2,143	28,217	63,426
Balance at 31 Dec, 2011	11,821	20,045	1,200	1,670	26,238	60,973
Profit for the period					712	712
Other com- prehensive income, net of tax:
Cash flow hedges				127		127
Translation differences				-106		-106
Total com- prehensive income for the period				21	712	733
Share-based payments					29	29
Balance at 31 Mar, 2012	11,821	20,045	1,200	1,691	26,977	61,735

1)"Other reserves" contains hedge reserve and translation differences.

CHANGES IN PROPERTY, PLANT AND EQUIPMENT

1,000 euro	1 Jan- 31 Mar, 2013	1 Jan- 31 Mar, 2012	1 Jan- 31 Dec, 2012
Carrying amount at the beginning of the period	43,433	34,887	34,887
Additions	2,569	2,592	14,342
Disposals	-	-	-
Depreciation	1,302	1,512	-5,739
Exchange differences	119	-120	-56
Carrying amount at the end of the period	44,819	35,847	43,433

COMMITMENTS AND CONTINGENCIES

1,000 euro	31 Mar, 2013	31 Mar, 2012	31 Dec, 2012
Loans, secured with collaterals	11,000	1,000	1,000
Collaterals	21,164	8,073	8,073
Off-balance sheet lease commitments	453	435	451
Capital commitments	2,376	6,199	5,499
Nominal values of derivative contracts
Currency options, call	895	-	-
Currency forward agreements	769	154	1,462
Electricity derivatives	        2,434	2,958	2,489
Fair values of derivative contracts
Currency options, call	2	-	-
Currency forward agreements	-11	5	21
Electricity derivatives	-199	-309	-227

The contract price of the derivatives has been used as the nominal value of the underlying asset.

HIERARCHY LEVELS OF DERIVATIVE CONTRACTS MEASURED AT FAIR VALUE

1,000 euro	31 Mar, 2013				31 Dec, 2012
Â	Level  1	Level  2	Level  3		Level  1	Level  2	Level  3
Financial assets	Â	Â	Â		Â	Â	Â
Derivative financial instruments	-	31	-		-	67	-
Â	Â	Â	Â		Â	Â	Â
Financial liabilities	Â	Â	Â		Â	Â	Â
Derivative financial instruments	-	240	-		-	274	-

Fair value estimation

The group's financial instruments that are measured at fair value comprise derivatives used for hedging and held for trading, and they are classified on hierarchy level 2.

Fair values of level 2 instruments are based on other data than quoted prices in active markets, but on the data from which the asset is observable, either directly (i.e. price) or indirectly (i.e. derived from the prices).

Fair value determination

The fair values of currency derivatives are determined by using mark-to-market method at the reporting date.

The fair values of electricity derivatives are determined on the basis of market quotations and contract prices of the instruments at the reporting date.

KEY FIGURES SHOWING FINANCIAL PERFORMANCE

1,000 euro	1 Jan- 31 Mar, 2013	1 Jan- 31 Mar, 2012	1 Jan- 31 Dec, 2012
Net sales	16,403	18,902	83,074
Change in net sales compared to the previous year's period, %	-13.2	-14.3	-0.1
Export and foreign operations share of net sales, %	92.5	95.1	94.4
Operating profit before depreciation (EBITDA)	2,725	3,052	13,864
    % of net sales	16.6	16.1	16.7
Operating profit	1,373	1,535	8,018
    % of net sales	8.4	8.1	9.7
Profit before tax	1,277	1,229	7,600
    % of net sales	7.8	6.5	9.1
Return on equity, %	7.8	4.6	8.3
Return on investment, %	6.6	7.9	11.8
Non-interest-bearing liabilities	14,972	15,857	18,309
Net interest-bearing liabilities	2,003	-6,071	-1,688
Net gearing ratio, %	3.2	-9.8	-2.7
Equity ratio, %	67.3	79.2	72.2
Capital expenditure	2,569	2,592	14,342
    % of net sales	15.7	13.7	17.3
Depreciation	1,352	1,517	5,846
Research and development expenditure	644	535	2,331
    % of net sales	3.9	2.8	2.8
Average number of personnel during the period	358	351	368
Personnel at the end of the period	354	352	364

KEY FIGURES PER SHARE

Euro	31 Mar, 2013	31 Mar, 2012	31 Dec, 2012
Basic earnings per share	0.07	0.04	0.31
Diluted earnings per share	0.07	0.04	0.30
Equity per share	3.80	3.69	3.72
Dividend per share	-	-	0.25
Dividends/earnings, %	-	-	80.6
Effective dividend yield, %	-	-	5.0
Price/earnings(P/E)	-	-	16.2
Share performance (1.1.-)
Average trading price	4.71	5.63	5.25
Lowest trading price	4.33	4.98	4.21
Highest trading price	5.15	6.01	6.01
Trading price at the end of the period	4.53	5.82	5.02
Market capitalisation at the end of the period, 1,000 euro	78,312	100,613	86,783
Trading volume (1 Jan-)
Trading volume, transactions, 1,000 pcs	1,004	1,141	3,330
In relation to weighted average number of shares, %	5.8	6.6	19.3
Trading volume, 1,000 euro	4,732	6,422	17,496
The weighted average number of shares during the period under review adjusted by the share issue, 1,000 pcs	17,288	17,288	17,288
The number of shares at the end of the period adjusted by the share issue, 1,000 pcs	17,288	17,288	17,288

QUARTERLY KEY FIGURES

1,000 euro	10-12/ 2013	7-9/ 2013	4-6/ 2013	1-3/ 2013
Net sales				16,403
  Compared to previous   quarter, %				-20.7
  Compared to corresponding   period last year, %				-13.2
Operating profit				1,373
  % of net sales				8.4
Profit before tax				1,277
  % of net sales				7.8
Net cash flow generated from: Operating activities				811
Investing activities				-4,131
Financing activities				9,904
Increase/decrease in cash and cash equivalents				6,585
Personnel at the end of the period				354

1,000 euro	10-12/ 2012	7-9/ 2012	4-6/ 2012	1-3/ 2012
Net sales	20,685	21,017	22,469	18,902
  Compared to previous   quarter, %	-1.6	-6.5	18.9	4.2
  Compared to corresponding   period last year, %	14.1	-1.1	3.3	-14.3
Operating profit	1,007	2,970	2,506	1,535
  % of net sales	4.9	14.1	11.2	8.1
Profit before tax	762	2,873	2,736	1,229
  % of net sales	3.7	13.7	12.2	6.5
Net cash flow generated from: Operating activities	3,565	4,209	2,616	-966
Investing activities	-2,650	-3,057	-2,652	-2,624
Financing activities	-91	-288	-1,493	-201
Increase/decrease in cash and cash equivalents	825	864	-1,529	-3,791
Personnel at the end of the period	364	365	390	352

DEFINITIONS OF KEY FINANCIAL FIGURES

Operating profit before depreciation (EBITDA)	=	Operating profit + depreciation
Return on equity (ROE), %	=	Profit/loss for the period x 100/
		Equity(Average for the period)
Return on investment (ROI), %	=	(Profit/loss before tax + interest and other financial expenses) x 100/
		Balance sheet total - non-interest bearing liabilities(average for the period)
Equity ratio, %	=	Equity x 100/
		Balance sheet total - advances received
Net interest-bearing liabilities	=	Interest-bearing liabilities - cash and cash equivalents
Net gearing ratio, %	=	(Interest-bearing liabilities - cash and cash equivalents) x 100/
		Equity
Earnings per share	=	Profit/loss for the period attributable to  equity holders of the parent company/
		Adjusted weighted average number of shares in issue during the period
Equity per share	=	Equity attributable to equity holders of the parent company/
		Adjusted number of shares at the end of the period
Dividend per share	=	Dividend for the period/
		Adjusted number of shares at the end of the period
Effective dividend yield, %	=	Dividend per share x 100/
		Trading price at the end of the period
Price/earnings ratio (P/E)	=	Last adjusted trading price at the end of the period/
		Earnings per share
Average trading price	=	Total traded amount in euro/
		Adjusted number of shares traded during the period
Market capitalisation at the end of the period	=	Number of shares at the end of the period x trading price at the end of the period
Trading volume	=	Number of shares traded during the period/
		Weighted average number of shares during the period

All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure.

The future estimates and forecasts in this interim report are based on the company management's current knowledge. Actual events and results may differ from the estimates presented here.

PRESS CONFERENCE

A press conference for the media and analysts will be held on Thursday, 25 April 2013 at 8.30 a.m. at the World Trade Center, Aleksanterinkatu 17, second floor, Helsinki. The result will be presented by President Kai Seikku. The press conference will be held in Finnish.

OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,
tel. +358 400 200 288, email: [e-mail]

Senior Vice President, Finance, IT, and Communications
Juha Jaatinen, Okmetic Oyj, tel. [phone],
email: [e-mail]

Distribution:
NASDAQ OMX Helsinki
Principal media
www.okmetic.com (http://www.okmetic.com/)

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise. Okmetic provides its customers with solutions that boost their competitiveness and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process. 

Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com.

OKME1313 (http://hugin.info/132025/R/1695946/558312.pdf)

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Okmetic Oyj via Thomson Reuters ONE

HUG#1695946